Testing drug responses using glioblastoma organoids
Official title: Patient-derived Organoids As Predictive Models for Drug Response Testing and Repurporsing in Glioblastoma Therapy
Run by Chungnam National University Hospital · NCT06782984 · Data updated 2026-11-12
This study is testing if lab-grown brain tumor samples from patients can help predict how well different drugs will work for their glioblastoma treatment.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 150 (estimated) |
| Sponsor | Chungnam National University Hospital Academic / other |
| Drugs / interventions | Lazertinib |
| Locations | 1 site (Daejeon, Chungcheongnam-do) |
| Status | Recruiting |
| Started | August 18, 2021 |
| Main results expected | December 2028 |
| Study ends | December 2030 |
| Registry record updated | January 20, 2025 |
| Trial ID | NCT06782984 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are patients with primary or recurrent glioblastoma who have undergone standard treatment including surgery and temozolomide-based chemoradiation therapy.
✕Probably not a fit
Patients who have not received concurrent chemoradiation therapy or those who refuse participation may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study evaluates the prognostic value of patient-derived glioblastoma organoids (GBOs) in predicting responses to conventional and repurposed drugs, including temozolomide, in patients with glioblastoma. The study aims to determine if the drug response observed in patients can be replicated in their corresponding GBOs. Utilizing a drug-response testing platform, the research assesses cell viability and explores the potential application of various chemotherapeutic agents. The goal is to collect diverse genetic information and validate the GBO model as a preclinical alternative to traditional clinical trials.
Why it matters
Potential benefit: If successful, this approach could lead to more personalized and effective treatment options for glioblastoma patients.
How similar studies have gone: Previous studies have shown promise in using organoid models for drug sensitivity testing, suggesting potential success for this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * primary or recurrent glioblastoma * patients treated with standard treatment including surgery and temozolomide based chemoradiation therapy * sufficient tumor sample is available for organoid culture Exclusion Criteria: * patients who are not underwent concurrent chemoradiation therapy (CCRT) following surgery * failed to obtain MRI scan after CCRT * patients refusal
Where it's running
-
Chungnam National University Hospital
Daejeon, Chungcheongnam-do, South Korea Recruiting
Study contacts
- Principal investigator: Kyung Hwan Kim, MD, PhD — Department of Neurosurgery, Chungnam National University Hospital
- Study coordinator: Kyung Hwan Kim, MD, PhD
- Email: nskhkim@cnuh.co.kr
- Phone: 82-42-280-7367
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
YN003 injection in glioma patients
This phase 1 study tests whether YN003 injected IV is safe and tolerable for adults with recurrent or progressive glioma, and to explore how the drug behaves in the body and any early signs of activity.
-
Brain connectome project in adults with brain glioma undergoing surgery
This registry collects MRI data and clinical information from adults with glioma to see how brain networks relate to surgery and recovery.
-
Organoid Drug Sensitivity-Guided Therapy for Refractory Tumors
This study tests whether tumor organoids created from a patient’s tissue can help doctors pick drugs for adults with hard‑to-treat, unresectable, or metastatic cancers after standard options have been exhausted.
-
Lixumistat window of opportunity in newly diagnosed glioblastoma
This study tests whether Lixumistat can benefit adults with newly diagnosed glioblastoma who are planned for surgical tumor removal.
-
Glioblastoma in Réunion: an epidemiological and socio-anthropological look at patients and care
A large group of adults with diffuse gliomas in Réunion is being studied to understand how biology, culture, and health care pathways affect diagnosis and treatment.
-
Butterfly glioblastoma: test adding 5-ALA PoMA with LIDU ultrasound to standard care
This early-phase study tests whether adding 5-ALA–mediated activation with LIDU ultrasound is safe and tolerable for adults with newly diagnosed butterfly glioblastoma, before or during standard chemotherapy and radiotherapy.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.